Board of Directors

Charles O’Hanlon
Thomas Petzinger, Jr.
Paul Kornblith, M.D.
Eric T. Ahrens, Ph.D.
Daniel P. Gallagher, Jr.
Ronald B. Herberman, M.D.
Kevin S. McClatchy
L. Gerald Tarantino
D. Lansing Taylor, Ph.D.

Charles F. O’Hanlon, President and CEO. Mr. O’Hanlon was previously a Managing Director of Cornerstone Capital Advisors, of Pittsburgh, PA, where he provided financial and operating advice, interim management, and corporate finance services to privately held businesses. While at Cornerstone, he was involved in the founding of numerous new ventures, spin-offs, and re-starts of distressed companies. Prior to joining Cornerstone in 2001, he held a number of executive management positions with National City and Mellon Bank. Mr. O’Hanlon serves on the boards of several private companies. He previously served on the boards of the Pittsburgh Technology Council, the CEO Venture Fund, and the Pittsburgh Regional Healthcare Initiative. He received a B.S. in industrial management from Georgia Institute of Technology and an MBA from Robert Morris College in 1980.

Thomas Petzinger, Jr., Secretary and Treasurer. Mr. Petzinger is also the CEO of LaunchCyte LLC, and serves as Executive VP of Business Development and Public Affairs for Knopp Neurosciences, Inc. He has formed five other life sciences ventures. He spent 22 years at The Wall Street Journal, where he served as Washington Economics Editor, deputy Washington Bureau Chief, Millennium Editor, and weekly columnist. A Pulitzer nominee for numerous investigative stories, he has also written three best-selling business books. He is a director of PABiotech. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.

Paul Kornblith, M.D., Chairman of the Board of Directors. Dr. Kornblith is a neurosurgeon, academic, inventor, and entrepreneur. He trained at Temple University, Jefferson Medical College, the University of Pennsylvania, and Massachusetts General Hospital. He was formerly a faculty member at Harvard University, Chief of Surgical Neurology at the NIH, Professor of Neurosurgery and Chairman at Albert Einstein College of Medicine, and Professor of Neurosurgery and Vice Chairman at the University of Pittsburgh. While at NIH his work led to the development of innovative chemosensitivity assays, and he also served as leader of the NIH PET program, discovering its value in clinical cancer management. In 1995, he founded and served as President and CEO of Precision Therapeutics, Inc., a cancer chemoresponse company. Presently, Dr. Kornblith is Adjunct Professor at the University of Pittsburgh School of Health and Rehabilitation Sciences. He is Western Pennsylvania Regional Director for PABiotech.

Eric T. Ahrens, Ph.D., Founder and Chief Scientific Officer. Dr. Ahrens is also an Associate Professor in the Department of Biological Sciences at Carnegie Mellon University. Dr. Ahrens earned his B.S. and Ph.D. degrees in physics from the University of California at Los Angeles and formally served for 6 years on the research faculty at the California Institute of Technology, Department of Biology. Dr. Ahrens is an expert in cellular-molecular MRI technologies and basic science applications utilizing MRI/NMR techniques. He is an author/inventor of more than 60 scientific articles and patent applications.

Daniel P. Gallagher, Jr., is a partner with the Pittsburgh office of Reed Smith. Mr. Gallagher’s legal practice is currently devoted to a wide variety of financial and international business, investment and joint venture transactions. Mr. Gallagher received his J.D. from the University of Chicago and his B.A. with Honors from Yale University.

Ronald B. Herberman, M.D., is Chief Medical Officer of Oncology for Intrexon, Inc. Formerly, Dr. Herberman was the Founding Director of the University of Pittsburgh Cancer Institute at the University of Pittsburgh Medical Center for 23 years. He is an internationally recognized tumor immunologist who has made major discoveries in his field, most notably the initial descriptions of natural killer (NK) cells, and he has fostered the application of this information to novel approaches to cancer therapy. His pioneering investigations of NK cells demonstrated their important role in resistance to the metastatic spread of cancer.

Kevin S. McClatchy is a private investor and a former media and entertainment company executive. Mr. McClatchy is currently a director of McClatchy Newspapers, Inc. From 1996 to 2007 he was the Managing General Partner and CEO of the Pittsburgh Pirates Major League Baseball team. Mr. McClatchy earned his B.A. in political science at University of California at Santa Barbara.

L. Gerald Tarantino, J.D., is a retired executive and private investor. Mr. Tarantino began his career as a Wall Street securities lawyer. For the past twenty-five years he has been the owner/manager of a range of small and medium sized businesses, both private and public, in diverse areas and industries, including sophisticated software, information technology, biotechnology, and the internet. He holds a B.A. and an LLB from the University of Pennsylvania.

D. Lansing Taylor, Ph.D., is the CEO of Cellumen, Inc., a cell-based drug discovery company, and founded Cellomics, Inc., where he was Chairman and CEO from 1996-2004. Prior to this he was a co-founder, member of the Board, and a scientific advisor to Biological Detection Systems, Inc. until it was sold to Amersham Biosciences in 1996. Dr. Taylor was formally a Professor of Biological Sciences, Vice Dean of Molecular Sciences and Director of the National Science Foundation, Science and Technology Center (STC) at Carnegie Mellon between 1982 and 1996. He began his academic and research career at Harvard University. Dr. Taylor is currently Chairman of the Board of Directors of the Pittsburgh Life Sciences Greenhouse, and a board member for NetHealth Systems, Inc. and PABiotech. He received the 1996 Computer World, Smithsonian Award in Science and was named entrepreneur of the year in Western Pennsylvania by Ernst and Young in 2001 and entrepreneur of the year in 2002 by the Carnegie Science Center and the Pittsburgh Technology Council. Dr. Taylor holds more than 12 patents.